TY - JOUR T1 - Optimizing Clinical Outcome and Toxicity in Lung Cancer Using a Genomic Marker of Radiosensitivity JF - medRxiv DO - 10.1101/2020.01.09.20017046 SP - 2020.01.09.20017046 AU - Jacob G. Scott AU - Geoff Sedor AU - Michael W. Kattan AU - Jeffrey Peacock AU - G. Daniel Grass AU - Eric A. Mellon AU - Ram Thapa AU - Michael Schell AU - Anthony Waller AU - Sean Poppen AU - George Andl AU - Steven A. Eschrich AU - Thomas J. Dilling AU - William S. Dalton AU - Louis B. Harrison AU - Tim Fox AU - Javier F. Torres-Roca Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/01/13/2020.01.09.20017046.abstract N2 - While radiation therapy serves as the backbone for nearly 40% of all cancer cures, and is received by nearly 70% of all cancer patients at some point in their cancer journey, it has yet to enter the modern era of personalized medicine. While field shape and size is personalized anatomically for all patients, the dose of radiation is still prescribed in a one-size-fits-all manner. Given the reality of inter-tumoral heterogeneity demonstrated by cancer sequencing efforts, we propose that we are working under an outdated null hypothesis in our field: that all patients should respond the same to the same dose of radiation. We have previously developed a method by which to predict optimal dosing for a given patient, which we term the Genomically Adjusted Radiation Dose, given the a priori knowledge of a patient’s tumor genomics. Knowing how much dose a patient’s tumor requires for biological optimization provides the first opportunity to characterize the inefficienies of one-size-fits-all dosing schemes, that result in both over- and under-dosing for the majority of patients. To elucidate this inefficiency, and therefore the opportunity to improvement using a personalized dosing scheme, we develop a competing hazards-style mathematical model combining the canonical equations for tumor control and normal tissue complication probabilities. Using data from two prospectively collected cohorts of patients with non-small-cell lung cancer, we show how the results of a recent uniform dose escalation study can be explained by the biological innefficiency of empiric uniform dose escalation, and highlight the opportunities for improvement in radiation outcomes available today, without need for new technology or equipment.Competing Interest StatementJGS and JTR are co-inventors of and own IP for GARD and RxRSI. JTR and SE are co-inventors of and IP for RSI. JTR and SE have stock in Cvergenx. JGS has stock options in Cvergenx. TF, GA and AW have shared interest and stock in Varian Medical Systems.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA ER -